intent-to-treat population using multiple imputation (ITT-MI) of subjects with prediabetes and/or MetS	placebo	incidence rate of type 2 diabetes	15740	15943	The annualized incidence rate of type 2 diabetes in this population was 6.1, 1.8, and 1.3 for placebo, 7.5/46, and 15/92 (reductions of 70.5% with 7.5/46 and 78.7% with 15/92; P < 0.05 vs. placebo; ITT).
intent-to-treat population using multiple imputation (ITT-MI) 	placebo	mean percent weight loss of subjects with prediabetes and/or MetS	1118	1322	After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo),
intent-to-treat population using multiple imputation (ITT-MI) of subjects with prediabetes and/or MetS	placebo	incidence rate of type 2 diabetes	1118	1503	After 108 weeks, subjects with prediabetes and/or MetS in the placebo, 7.5/46, and 15/92 groups experienced mean percent weight loss of 2.5, 10.9, and 12.1%, respectively (ITT-MI; P < 0.0001 vs. placebo), associated with reductions of 70.5 and 78.7% in the annualized incidence rate of type 2 diabetes for those receiving 7.5/46 and 15/92, respectively (ITT, P < 0.05), versus placebo.
